[Biallelic inactivation of the p16-Gen in a metachronous triple carcinoma in the oropharyngeal region]

Laryngorhinootologie. 2004 Jan;83(1):55-60. doi: 10.1055/s-2004-814111.
[Article in German]

Abstract

Aims: Recent studies have shown that most Dutch families with atypical multiple-mole melanoma (FAMMM) have a 19-bp deletion (p16-Leiden) in exon 2 of the p16 gene. Apart from reports on metachronous pancreatic tumors, other cancer types have never been described in such families. Due to heterozygous p16-Leiden constitution, our proband with multiple head and neck carcinomas was a suitable model for studying the type of p16 inactivation according to the Knudson-two-hit model.

Methods: p16 mutations in exons 1 and 2 were determined using PCR-SSCP-Sequencing analysis. p16 methylation was assessed by methylation-specific PCR.

Results: All three metachronous (larynx, pharynx, oral cavity) tumors had a methylated p16 promotor. The p16 protein loss detected by immunohistochemistry clearly confirmed a complete loss of p16 tumor suppressor function. Thus, all three tumors exhibited biallelic inactivation of p16, caused by aberrant methylation of the p16 promotor.

Conclusions: This is the first report on p16-Leiden mutation in head and neck cancer. We provide evidence that the somatic methylation of p16 promotor is associated with the germline transmission of p16-Leiden mutation. This is an example for the rare event of in which aberrant methylation acting as the 'second hit' in a familial cancer syndrome. Our results show that this epigenetic event is equivalent to genetic alterations (mutation/LOH) confirming the Knudson's hypothesis for tumor suppressor gene inactivation.

Publication types

  • Case Reports
  • Comparative Study
  • English Abstract

MeSH terms

  • Carcinoma, Squamous Cell / genetics*
  • Carcinoma, Squamous Cell / radiotherapy
  • Carcinoma, Squamous Cell / surgery
  • Cyclin-Dependent Kinase Inhibitor p16 / genetics*
  • DNA Methylation
  • DNA, Neoplasm / genetics
  • Follow-Up Studies
  • Gene Expression Regulation, Neoplastic
  • Genes, p16*
  • Head and Neck Neoplasms / genetics*
  • Humans
  • Immunohistochemistry
  • Karnofsky Performance Status
  • Laryngeal Neoplasms / genetics*
  • Laryngeal Neoplasms / radiotherapy
  • Laryngeal Neoplasms / surgery
  • Male
  • Middle Aged
  • Mouth Neoplasms / genetics*
  • Mouth Neoplasms / surgery
  • Mutation*
  • Neoplasms, Second Primary / genetics*
  • Pharyngeal Neoplasms / genetics*
  • Pharyngeal Neoplasms / radiotherapy
  • Pharyngeal Neoplasms / surgery
  • Polymerase Chain Reaction
  • Promoter Regions, Genetic
  • Radiotherapy Dosage
  • Time Factors

Substances

  • Cyclin-Dependent Kinase Inhibitor p16
  • DNA, Neoplasm